Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company wholesales pharmaceutical products.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,399 | 5,163 | 5,060 | 6,688 | 9,919 | 4,645 | 5,536 | +3.9% |
| Total COGS | 2,375 | 2,218 | 2,251 | 3,002 | 4,240 | 1,642 | 1,960 | -3.2% |
| Gross Profit | 2,024 | 2,945 | 2,809 | 3,686 | 5,679 | 3,003 | 3,576 | +10.0% |
| Gross Margin | 46.0% | 57.0% | 55.5% | 55.1% | 57.3% | 64.6% | 64.6% | |
| 1,123 | 1,374 | 2,351 | 2,172 | 2,832 | 1,809 | 2,019 | +10.3% | |
| EBITDA | 901 | 1,571 | 458 | 1,515 | 2,848 | 1,194 | 1,558 | +9.5% |
| EBITDA Margin | 20.5% | 30.4% | 9.1% | 22.6% | 28.7% | 25.7% | 28.1% | |
| Total D&A | 40 | 0 | 38 | 41 | 40 | 36 | 39 | -0.6% |
| EBIT / Operating Income | 861 | 1,571 | 420 | 1,473 | 2,808 | 1,158 | 1,519 | +9.9% |
| Total Interest Income | 0 | 9 | 2 | 0 | 0 | 0 | 0 | -74.3% |
| Total Interest Expense | 74 | 74 | 87 | 57 | 51 | 40 | 23 | -17.9% |
| Total Other Income | 6 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 792 | 1,506 | 336 | 1,416 | 2,757 | 1,118 | 1,496 | +11.2% |
| Total Income Tax | 0 | 151 | 115 | 246 | 291 | 405 | 172 | +2.6% |
| Net Profit / (Loss) | 901 | 1,355 | 221 | 1,170 | 2,466 | 712 | 1,324 | +6.6% |
| Net Margin | 20.5% | 26.2% | 4.4% | 17.5% | 24.9% | 15.3% | 23.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →